The importance of inflammation in CVD progression was recently demonstrated by the CANTOS trial that showed marked reduction of cardiovascular events in patients with CKD that had had myocardial infarction beforehand when treated with interleukin (IL)-1β antibody canakinumab. This evidence concerns the gene IL1B and chronic kidney disease.